Collegium Pharmaceutical, Inc.
COLLHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Sep 8, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Collegium Pharmaceutical, Inc. focuses on Drug Manufacturers - Specialty & Generic services and products. Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Valued at $729.4M, COLL is a small-cap name in its sector. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
Market Cap
$729.4M
Beta
0.72
P/E (TTM)
18.53
P/E (Fwd)
3.48
EPS (TTM)
$1.27
EPS (Fwd)
$6.77
ROE
17.6%
ROA
5.8%
Cash
$129.5M
Total Debt
$1.22B
Free CF
$324.0M
52W Change
-38.0%
Annual Financials
Cash vs Debt
Where COLL stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, COLL finished 31.24% below its 150-day moving average ($35.34) and 36.52% below its 200-day moving average ($38.28). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is COLL overbought or oversold?
At the September 3, 2026 close, COLL's RSI(14) was 21.5, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $129.5M in cash, though total debt stands at $1.22B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $324.0M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 17.6% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 5.8% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $463.9M (2022) to $780.6M (2025), reflecting a 68% increase over the period.
The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Collegium Pharmaceutical, Inc. and its sector.